2021 Fiscal Year Final Research Report
Gene expression profiling using targeted RNA seqencing in early stage lung adenocarcinoma wiht a solid component or micropapillary component
| Project/Area Number |
19K18214
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 55040:Respiratory surgery-related
|
|---|
| Research Institution | Tottori University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | 浸潤性肺腺癌 / 充実型増殖 / 発現変動遺伝子 |
|---|
| Outline of Final Research Achievements |
Lung adenocarcinoma (LUAD) has histologically intratumor heterogeneity. Especially, a solid component and a micropapillary component are highly malignant, and even in LUAD of the same stage, the presence of these two subtypes shows a poor prognosis. Therefore, we studied the genetic characteristics of these two subtypes.
First, tissues were collected from the stage I LUAD resected specimens using a laser microdissection for a solid component and a acinar component which is the one of the subtypes of LUAD. Second, RNA was collected from the tissue and we compared the RNA in the solid component with the acinar component. However, in the micropapillary type, pure tissue was not cut out. Finally, the analysis was performed only in the solid component compared with the acinar component. Many RNAs involved in cell proliferation were found in a solid component. In addition, PDL1 was highly expressed in a solid component, suggesting the involvement of immunosuppression.
|
| Free Research Field |
呼吸器外科
|
| Academic Significance and Societal Importance of the Research Achievements |
肺腺癌の中で，とくに予後不良となる充実型増殖の遺伝子発現状況の研究を行い多数の遺伝子の発現上昇あるいは発現低下を確認した．すでに免疫療法として治療対象となっているPDL1が充実型で多く見れらた．加えて，乳癌領域で癌遺伝子の調節を行う因子として報告されているTAF1の発現上昇，転移抑制として働き癌抑制因子としての機能が知られているHOXB3の発現低下，過去の報告で肺癌の増殖能を活性化する可能性が示されているPSMA6などが見られた．さらなる研究は必要であるが，これらの遺伝子は肺癌の新規治療の標的となりえ，予後不良な肺癌の治療に貢献できる可能性がある．
|
